# Equivalence Study to Compare Two Strengths of Creon in China

> **NCT03450772** · PHASE3 · UNKNOWN · sponsor: **Abbott** · enrollment: 60 (estimated)

## Conditions studied

- Pancreatic Insufficiency

## Interventions

- **DRUG:** Creon® 25000
- **DRUG:** Creon® 10000

## Key facts

- **NCT ID:** NCT03450772
- **Lead sponsor:** Abbott
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-08-31
- **Primary completion:** 2022-04
- **Final completion:** 2022-04-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03450772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03450772, "Equivalence Study to Compare Two Strengths of Creon in China". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03450772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*